Inhibitors of Type II NADH-dehydrogenase, Cytochrome bd Oxidase, and ATP Synthase for Anti-tubercular Response

Key Points

• To identify new anti-tubercular agents that effectively combat drug-resistant tuberculosis.
• Focused on inhibitors of Type II NADH-dehydrogenase, Cytochrome bd Oxidase, and ATP Synthase.
• Targeting Mycobacterium tuberculosis to elicit lethal responses.
• Demonstrated efficacy against drug-resistant strains.
• Potentially significant reduction in mortality from tuberculosis.